Biomarkers of inflammation and amyloid-β phagocytosis in patients at risk of Alzheimer disease
- 21 August 2009
- journal article
- review article
- Published by Elsevier in Experimental Gerontology
- Vol. 45 (1) , 57-63
- https://doi.org/10.1016/j.exger.2009.08.003
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Clearance of Amyloid-β Peptide Across the Blood-Brain Barrier: Implication for Therapies in Alzheimers DiseaseCNS & Neurological Disorders - Drug Targets, 2009
- Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderlyAnnals of Neurology, 2009
- Alzheimer disease macrophages shuttle amyloid-beta from neurons to vessels, contributing to amyloid angiopathyActa Neuropathologica, 2009
- CSF and MRI markers independently contribute to the diagnosis of Alzheimer's diseaseNeurobiology of Aging, 2008
- Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcuminProceedings of the National Academy of Sciences, 2007
- Cerebrospinal Fluid tau/β-Amyloid42 Ratio as a Prediction of Cognitive Decline in Nondemented Older AdultsArchives of Neurology, 2007
- Proteome-based plasma biomarkers for Alzheimer's diseaseBrain, 2006
- Increased intrathecal TGF-β1, but not IL-12, IFN-γ and IL-10 levels in Alzheimer’s disease patientsNeurological Sciences, 2006
- Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathologyInternational Journal of Developmental Neuroscience, 2005
- Decreased β-Amyloid1-42and Increased Tau Levels in Cerebrospinal Fluid of Patients With Alzheimer DiseaseJAMA, 2003